Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits

American Journal of Health-System Pharmacy

Volumn 64, Issue 13 SUPPL., 2007, Pages

  Gilmartin, Cheryl ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anemia; Compliance; Continuous erythropoiesis receptor activator; Darbepoetin alfa; Diagnosis; Dialysis; Dosage schedules; Drug administration routes; Drug interactions; Economics; Hematopoietic agents; Iron; Iron preparations; Kidney diseases; Patient information

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AWARENESS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; ECONOMIC ASPECT; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DEPARTMENT; HUMAN; HYPERTENSION; MALNUTRITION; MEDICARE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PERIPHERAL EDEMA; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; RHINOPHARYNGITIS;

EID: 34347405959     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070183     Document Type: Conference Paper

References (44)

1. United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. www.usrds.org/adr.htm (accessed 2007 Feb 7).
2. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and urologic diseases statistics for the United States. kidney.niddk.nih.gov/ kudiseases/pubs/kustats/index.htm (accessed 2007 Feb 11).
3. Ad Hoc Committee on Nephrology Manpower Needs. Estimating workforce and training requirements for nephrologists through the year 2010. J Am Soc Nephrol. 1997 May; 8(5 suppl 9):S9-13, i-xxii, 1-32 passim.
4. Thorp ML, Eastman L, Smith DH et al. Managing the burden of chronic kidney disease. Dis Manag. 2006; 9:115-21.
5. Bennett RE, DeHart RM, Lauderdale SA. Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease. Am J Health-Syst Pharm. 2006; 63:2123-7.
6. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(5 suppl 3):S11-145.
7. Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002; 22:1533-40.
8. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001; 21:1337-44.
9. Cioffi ST, Caron MF, Kalus JS et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004; 38:771-5.
10. Morello CM, Zadvorny EB, Cording MA et al. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health-Syst Pharm. 2006; 63:1325-31.
11. Scott DM, Boyd ST, Stephan M et al. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health-Syst Pharm. 2006; 63:2116-22.
12. Naughton CA. Establishing pharmaceutical services on a renal dialysis unit. Am J Health-Syst Pharm. 2002; 59:2111-2.
13. Kimura T, Arai M, Masuda H et al. Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. Biol Pharm Bull. 2004; 27:1831-3.
14. Grabe DW, Low CL, Bailie GR et al. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997; 47:117-21.
15. Viola RA, Abbott KC, Welch PG et al. A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrol. 2002; 3:9.
16. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584-90.
17. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16:2180-9.
18. Eckardt KU. The CREATE trial - building the evidence. Nephrol Dial Transplant. 2001; 16(suppl 2):16-8.
19. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
20. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.
21. Remuzzi G, Ingelfinger JR. Correction of anemia - payoffs and problems. N Engl J Med. 2006; 355:2144-6.
22. Germain M, Ram CV, Bhaduri S et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005; 20:2146-52.
23. Provenzano R, Bhaduri S, Singh AK et al. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005; 64:113-23.
24. Ling B, Walczyk M, Agarwal A et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005; 63:327-34.
25. Sousa A, Vinhas J. Darbepoetin alfa (DbA) in patients (pts) with chronic kidney disease (CKD) once monthly (QM) clinical experience with SureClick. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
26. Hoggard J, Crouch T, McMurray S et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2006; 22:2023-30.
27. Price M, Holdener K, Leverson G. Outpatient RN + pharmacist-driven anemia clinic in stage 3-4 CKD: efficacy and impact on disease progression. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
28. Anon. Section IV. Failure to respond to treatment. Nephrol Dial Transplant. 2004; 19(suppl 2):ii32-ii36. www.ndt-educational.org/images/ New%20EBPG%20Anaemia%20Part%20III.pdf (accessed 2007 Feb 11).
29. de Francisco AL, Sulowicz W, Klinger M et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60:1687-96.
30. Locatelli F, Villa G, Arias M et al. CERA (continuous erythropoiesis receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every four weeks. Presented at the 37th Annual Meeting and Scientific Exposition of the American Society of Nephrology, St. Louis, MO: October 29-November 1, 2004. Abstract SU-PO051.
31. Dutka P, Tilocca P. CERA (continuous erythropoietin receptor activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race, or diabetic status. Presented at the American Nephrology Nurses' Association 37th National Symposium; Nashville, TN: April 2-5, 2006.
32. Provenzano R, Besarab A, Macdougall IC et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis. J Am Soc Nephrol. 2005; 16:760A.
33. MacDougall C, Walker R, Provenzano R et al. CERA administered at extended intervals corrects anemia and maintains stable Hbg levels in patients with CKD not on dialysis. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
34. Joy M. Anemia management in pre-dialysis chronic kidney disease. A pharmacist-provided CKD anemia management clinic. Presented at the 40th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; Las Vegas, NV: December 4, 2005.
35. Kausz AT, Khan SS, Abichandani R et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001; 12:1501-7.
36. McEvoy GK, ed. Iron preparations, oral. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1410-7.
37. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. www.kidney.org/professionals/ KDOQI/guidelines_updates/doqi_uptoc.html#an (accessed 2007 Feb 12).
38. Garsha J, Schwartz A. Prevalence of iron deficiency anemia of chronic kidney disease stage 3 and stage 4. Presented at the National Kidney Foundation Spring Clinical Meetings, Chicago, IL April 19-23, 2006.
39. McEvoy GK, ed. Iron sucrose. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1417-8.
40. Venofer package insert. Shirley, NY: American Regent, Inc; October 2005.
41. McEvoy GK, ed. Sodium ferric gluconate. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1418-22.
42. Ferrlecit package insert. Corona, CA: Watson Pharma, Inc. September 2006.
43. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to i.v. iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007; 18:975-84.
44. Akers GR, Brown BL, Roberts SS et al. Outpatient erythropoietin administered via a protocol-driven pharmacist-overseen program is associated with significant patient and economic benefits. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.